TACSTD2 and adenocarcinoma: In a study by Inamura et al., high TROP-2 expression levels were associated with high mortality in patients with adenocarcinoma (overall survival, HR = 1.49, 95% CI 1.06–2.13, p = 0.021) and longer overall survival in patients with high-grade neuroendocrine tumor (HGNET), (HR = 0.50, 95% CI 0.12–0.65, p = 0.0015), whereas no association was found with squamous-cell carcinoma (HR = 1.33, 95% CI 0.74–25.8), p = 0.35) [25].